Can Ketamine Therapy Help You Quit Nicotine?

Why Nicotine Addiction Is Hard to Quit

Nicotine dependence is a neurological condition, not a failure of willpower. When you consume nicotine, it hijacks your brain's dopamine reward pathway.

Your brain quickly learns to associate smoking or vaping with relief, pleasure, and stress reduction. Several specific mechanisms make nicotine uniquely difficult to quit:

• Neurochemical reinforcement: Nicotine triggers a rapid dopamine release in the nucleus accumbens, which is the brain's reward center.⁸ Over time, your baseline dopamine drops, making you dependent on nicotine just to feel normal.
• Withdrawal symptoms: Physical withdrawal begins within hours of your last cigarette and peaks within days.⁹ Symptoms like irritability, anxiety, difficulty concentrating, and insomnia create a powerful trigger for relapse.
• Cue-conditioned cravings: Environmental and emotional triggers become deeply associated with smoking. Stress, social situations, or morning routines can cause cravings to persist long after physical withdrawal subsides.
• Mood entanglement: Many people who smoke also experience anxiety or depression. Nicotine functions as a short-acting mood regulator, making it harder to quit without addressing the underlying emotional driver.

Conventional cessation tools like nicotine replacement therapy (NRT), varenicline, and behavioral counseling help many people. However, relapse rates remain high, particularly for those with co-occurring mood conditions.

This is the context in which researchers have begun exploring new options. Medical professionals are investigating whether ketamine's neuroplastic properties could offer an additional pathway for recovery.

What Research Says About Ketamine and Smoking Cessation

Ketamine is a well-understood pharmaceutical agent — FDA-approved as an anesthetic since 1970 and on the WHO List of Essential Medicines since 1985.¹ The research on its application specifically for smoking or nicotine cessation is evolving, while the robust evidence base for ketamine therapy applies to depression, anxiety, and PTSD.

For nicotine, the central question is whether ketamine's established mechanisms translate to addiction-related outcomes. Researchers are looking closely at neuroplasticity, glutamate modulation, and mood improvement, and several key pieces of evidence help inform the current clinical understanding:

• Preclinical and mechanistic research: Studies on ketamine's glutamate modulation suggest it may interfere with the reconsolidation of drug-associated memories.² This is the biological process by which cue-triggered cravings are maintained in the brain.
• Pilot and exploratory studies: A small body of clinical work has examined ketamine's effects on cue-induced craving in substance use contexts.³ Most addiction-related ketamine research has focused on alcohol and cocaine rather than nicotine specifically, and sample sizes remain small.
• Indirect evidence from mood outcomes: Ketamine's well-documented efficacy for depression and anxiety is highly relevant because mood symptoms are a major driver of continued nicotine use. Large-scale, real-world studies conducted on Mindbloom clients using the Mindbloom protocol demonstrate significant mood symptom improvement.⁴ ⁵

These large studies evaluated depression and anxiety outcomes rather than nicotine abstinence directly. However, the clinical overlap matters significantly for relapse prevention.

No large-scale randomized controlled trial has established ketamine as a standalone smoking cessation treatment. The current evidence is best described as mechanistically promising but clinically preliminary for nicotine specifically.

How Ketamine Therapy May Disrupt Nicotine Addiction Patterns

Ketamine's primary therapeutic mechanism is increasing neuroplasticity in the brain. This biological mechanism is the same regardless of the condition being treated.

The same process that allows people to break entrenched depressive thought patterns may also apply to habitual cravings. This concept can be framed as "one mechanism, multiple applications."

Ketamine may open a neuroplastic window during which entrenched behavioral and emotional patterns become more amenable to change — but that window is most valuable when paired with intentional behavioral work and clinical support. It does not directly eliminate cravings or withdrawal; it's a catalyst for the active work of habit change.

This window of flexibility is most valuable when paired with intentional behavioral work and clinical support.

Neuroplasticity: Breaking Entrenched Behavioral Loops

Neuroplasticity refers to the brain's ability to form new synaptic connections and reorganize existing ones. Ketamine promotes this flexibility by modulating glutamate signaling.

It also increases brain-derived neurotrophic factor (BDNF), a protein that acts like fertilizer to support the growth of new neural pathways.¹⁰ Nicotine dependence is sustained by rigid behavioral loops that resist conscious override.

These are automatic, deeply wired sequences that follow a strict pattern of trigger, craving, use, and relief. Ketamine's neuroplastic window may make these loops more flexible.

This temporary flexibility allows a person to interrupt the automatic sequence and practice alternative responses. This is the exact same mechanism behind ketamine's efficacy for treatment-resistant depression.

Addressing the Anxiety and Depression That Fuel Nicotine Use

Nicotine often functions as a self-medication tool for underlying mood conditions. Many people who smoke report that cigarettes help them manage anxiety, stress, or depressive episodes.

Unfortunately, nicotine's mood benefits are short-lived and ultimately create a dependency cycle. Rates of smoking are significantly higher among people with anxiety disorders, depression, and PTSD compared to the general population.⁶

If ketamine therapy reduces the severity of anxiety or depressive symptoms, a person's reliance on nicotine as a coping mechanism may decrease. The nicotine craving is not directly eliminated, but the emotional need it was serving is addressed through a healthier pathway.

This is an indirect mechanism for habit change. It serves as a clinically meaningful supporting factor in a broader quit strategy, rather than direct evidence that ketamine treats nicotine addiction.

Who Might Be a Good Fit for Ketamine Therapy for Nicotine Habits

Ketamine therapy is not currently prescribed specifically for nicotine cessation. However, people who want to quit nicotine and also have a qualifying diagnosis may find that ketamine therapy supports their quit effort.

Qualifying diagnoses typically include anxiety, depression, or PTSD. Eligibility is a clinical assessment process, not a self-diagnosis.

A licensed clinician will evaluate your medical history, psychiatric history, current medications, and treatment goals. The profile of someone who may benefit includes:

• Adults with a co-occurring mood condition who also want to address nicotine dependence.
• People who have tried conventional cessation methods with limited success and suspect that underlying mood symptoms are driving their relapse.
• Individuals motivated to engage in behavioral support and integration work alongside ketamine sessions.

Individuals who should discuss fit carefully with a clinician include:

• Individuals with certain cardiovascular conditions, uncontrolled hypertension, or other contraindications.
• People without a qualifying psychiatric diagnosis, since ketamine therapy requires a clinician-determined medical need.
• Anyone seeking ketamine solely as a nicotine cessation drug without a willingness to engage in the behavioral components.

How to Start Ketamine Therapy With a Quit Plan

If you and your clinician determine that ketamine therapy is appropriate, the most effective approach is to pair it with a defined quit plan. Treating ketamine as a standalone intervention for habit change is rarely effective.

The key principle is that ketamine opens a neuroplastic window. What you do during and after that window determines whether the change sticks.

A quit plan that combines clinical oversight, behavioral support, and integration gives you the best chance of success. This translates neuroplastic potential into lasting habit change.

Step 1: Set a Nicotine Goal With a Clinician

Before beginning ketamine sessions, work with your clinician to define a clear, realistic nicotine goal. This might be full cessation, a taper plan, or a reduction of use as a starting milestone.

Your clinician can assess your baseline nicotine use and identify your primary triggers. They will also help determine how your quit timeline aligns with your ketamine treatment plan.

Having a defined goal before the first session gives your integration work a concrete focus.

Step 2: Pair Ketamine Sessions With Behavioral Support

Ketamine therapy is most effective when combined with behavioral support. This could include one-on-one coaching, cognitive behavioral techniques, or educational programming.

These tools are designed to help you identify and interrupt automatic behavioral patterns. Mindbloom's Habit Change program, for example, integrates ketamine sessions with expert-designed behavioral content and guide coaching.

Eligibility for this program is determined through clinician assessment and typically involves conditions such as anxiety, depression, or PTSD when ketamine therapy is medically appropriate. The neuroplastic window ketamine creates is most valuable when you are actively working on new coping skills.

Step 3: Use Integration to Work With Cravings and Triggers

Integration is the practice of reflecting on and applying insights from ketamine sessions to daily life. For nicotine cessation, this means using the post-session period to actively rewire your habits.

• Identify your strongest cravings and the specific situations that trigger them.
• Practice alternative responses, such as breathing exercises, movement, or journaling, when a trigger arises.
• Discuss your patterns with a guide or in a group integration setting to build accountability and self-awareness.

Integration is an ongoing practice that helps translate the neuroplastic flexibility from each session into durable behavioral change. Mindbloom's care model includes guide coaching sessions and unlimited Group Integration Circles to provide ongoing support.

How Mindbloom's Clinical Protocols Support Safer At-Home Ketamine Therapy

Clinical protocols are the defined safeguards that distinguish therapeutic ketamine use from unsupervised or recreational use. For at-home ketamine therapy specifically, protocols must account for the fact that sessions occur outside a clinical facility.

Mindbloom's model is designed to deliver clinically rigorous care from the comfort of home. Key components of this clinician-supervised framework include:

• Clinical screening and eligibility: Every client undergoes a clinician-led evaluation of their medical history, psychiatric history, and current medications. Contraindications are carefully assessed during this process.
• Clinician-determined dosing: Mindbloom uses sub-anesthetic, clinician-determined therapeutic dosing. Treatment frequency is personalized based on individual needs and clinical guidance.
• Peer treatment monitor requirement: A peer treatment monitor is required to be present during every session. This is a non-negotiable safety protocol, not a recommendation.
• Guide coaching and integration: Each program includes guide coaching sessions, unlimited guide messaging, and unlimited Group Integration Circles.
• Subcutaneous option: Mindbloom is the only at-home ketamine provider offering subcutaneous administration (Injectables) in addition to sublingual tablets. This enables more consistent dosing for clients who prefer it.

Building on decades of clinical research, Mindbloom has published two of the largest peer-reviewed outcomes studies of at-home ketamine therapy to date.⁴ ⁵ Side effects occur at approximately 4–5% of sessions, adverse events at less than 0.1%, and discontinuation at 0.4%.⁴ ⁵

Ketamine therapy is not smoked. Mindbloom's clinical protocols use prescribed sublingual or subcutaneous administration under clinician supervision, not smoking ketamine.

The safety of at-home ketamine therapy is a function of clinical supervision, screening, and these strict protocols. Mindbloom's New Client 6-session program costs $215 per session, billed as three monthly installments of $430 for a total of $1,290.

Conclusion

Ketamine's neuroplastic mechanism is mechanistically relevant to addiction patterns — the same process well documented for depression, anxiety, and PTSD. It is not yet an established nicotine cessation treatment, but the biological basis for exploration is sound.

For people with co-occurring mood conditions who also want to quit nicotine, clinician-supervised ketamine therapy may offer a meaningful additional pathway. The evidence for nicotine specifically remains preliminary.

Any quit effort should involve clinical guidance, a defined goal, and ongoing behavioral support. Ketamine is not a passive solution, but rather a tool that opens a window for active engagement and integration.

Mindbloom's Habit Change program is designed to help clients replace harmful habits with beneficial ones. Eligibility begins with a comprehensive clinician assessment to ensure the treatment aligns with your medical history.

Disclaimer and Safety Information

IMPORTANT SAFETY INFORMATION
‍Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

‍OFF-LABEL USE DISCLOSURE‍
‍Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.